№ lp_1_2_36385
File format: docx
Character count: 37055
File size: 131 KB
Year:
2024
Region / City:
England
Topic:
Immunization
Document Type:
Patient Group Direction (PGD)
Organization / Institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Dr. Colin NJ Campbell, David Green
Target Audience:
Healthcare practitioners, immunization service providers
Effective Period:
From 22 August 2024
Approval Date:
22 August 2024
Amendment Date:
26 July 2023
Expiry Date:
31 August 2026
Review Date:
31 March 2026
Responsible Authority:
UK Health Security Agency (UKHSA)
Version:
v5.00
Change Details:
Updated instructions for vaccine administration, storage, and clinical content.
Description:
Document outlines the procedures and responsibilities for administering the BCG Vaccine AJV, with updated clinical guidance and regulatory compliance information.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / City:
London
Topic:
Neonatal BCG vaccination program
Document Type:
Protocol
Organization / Institution:
NHSE
Author:
Alice Waters
Target Audience:
Healthcare professionals involved in neonatal care and immunization
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
September 2025
Year:
2018
Region / city:
Belgium
Topic:
BCG therapy, bladder cancer, clinical trials
Document type:
Guidelines
Author:
Refvan de Putte EEF, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, et al.
Target audience:
Medical professionals, urologists
Period of validity:
Indefinite (as of 2018)
Approval date:
2018
Date of changes:
N/A
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience:
Healthcare professionals involved in immunization
Period of validity:
From 5 January 2026 to 5 January 2029
Approval date:
5 January 2026
Amendment date:
2 June 2025, 16 December 2025
Description:
A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Year:
2025
Region / city:
England
Topic:
Influenza immunisation
Document type:
Patient Group Direction (PGD)
Organisation:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Jamie Lopez-Bernal, Greta Hayward
Target audience:
Healthcare practitioners, NHS organisations
Period of validity:
From 1 September 2025 to 1 April 2026
Approval date:
3 July 2025
Revision history:
Updated annually, latest update 9 July 2025
Reference no:
HPV (GBMSM) PGD
Version no:
v5.0
Valid from:
1 September 2025
Review date:
1 April 2028
Expiry date:
1 September 2028
Author:
Suki Hunjunt, Sharif Ismail, David Green
Region / city:
England
Target audience:
Healthcare practitioners administering HPV vaccine to GBMSM
Type of document:
Patient Group Direction
Organisation:
UK Health Security Agency (UKHSA)
Date of approval:
17 July 2025
Date of modifications:
16 July 2025
Context:
A formal Patient Group Direction for the administration of HPV vaccine to GBMSM, detailing legal, clinical, and procedural requirements for healthcare practitioners in England.
Reference no:
Hib/MenC PGD
Version no:
v6.0
Valid from:
1 July 2025
Expiry date:
30 April 2026
Authorising organisations:
UK Health Security Agency (UKHSA)
Target audience:
Registered healthcare practitioners
Responsible body:
UKHSA
Note:
Amendment history
v1.0 and v2.0:
See previous versions of this PGD template for details (19 January 2016 to 23 April 2018)
v3.0:
PHE Hib/MenC PGD amended to: include vaccination of individuals for the prevention of secondary cases of meningococcal group C disease (24 April 2018)
v4.0:
PHE Hib/MenC PGD amended to: remove reference to individuals with an underlying medical condition (5 March 2020)
v5.0:
UKHSA Hib/MenC PGD amended to: include minor rewording of standard text, layout and formatting changes (4 May 2022)
v6.0:
UKHSA Hib/MenC PGD amended to: include minor rewording, updated references, and changes to the childhood immunisation schedule (2 June 2025)
Developed by:
Christina Wilson (Lead Pharmacist), Professor Shamez Ladhani (Paediatric Infectious Diseases Consultant), David Green (Nurse Consultant for Immunisation Programmes)
Peer-reviewed by:
UKHSA Immunisations PGD Expert Panel
Date approved:
2 June 2025
Year:
2025
Region:
England
Subject:
Hepatitis B vaccination for renal patients
Document Type:
Patient Group Direction (PGD)
Authorising Organisation:
UK Health Security Agency (UKHSA)
Target Audience:
Registered healthcare professionals
Period of Validity:
28 February 2025 - 28 February 2028
Approval Date:
28 February 2025
Amendment Date:
21 February 2025
Year:
2024
Region / city:
England
Topic:
Vaccination
Document type:
Patient Group Direction
Organization:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr. Mary Ramsay, David Green
Target audience:
Registered healthcare practitioners
Period of validity:
10 October 2024 - 30 April 2027
Approval date:
4 October 2024
Amendments date:
9 October 2024
Note:
Year
Organization / Institution:
NHS Scotland
Author:
Dr Laura Ryan, Dr John McAnaw, Mr Jim Miller
Target Audience:
Qualified health professionals within NHS Scotland
Changes History:
Eligibility age extended, new conditions added, clarifications made
Clinical Situation:
Acute uncomplicated urinary tract infection (UTI) in non-pregnant females aged 16 years and over.
Year:
2024
Region / City:
Scotland
Topic:
Pharmaceutical Guidelines
Document Type:
Patient Group Direction (PGD)
Organization / Institution:
NHS Scotland
Author:
Dr. Ronald Cook, Dr. John McAnaw
Target Audience:
Community Pharmacists
Effective Date:
20th February 2024
Expiry Date:
19th February 2027
Year:
2026
Region / city:
England
Topic:
Vaccination
Document type:
Patient Group Direction (PGD)
Organization:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr Vanessa Saliba, David Green
Target audience:
Healthcare practitioners
Validity period:
20 January 2026 – 30 November 2028
Approval date:
20 January 2026
Review date:
31 May 2028
Expiry date:
30 November 2028
Note:
Change history
Year:
2025
Region / city:
England
Topic:
Vaccination
Document type:
Patient Group Direction (PGD)
Issuing organization:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr. Vanessa Saliba, David Green
Target audience:
Healthcare practitioners authorized to administer vaccines
Valid from:
1 January 2026
Review date:
31 May 2028
Expiry date:
30 November 2028
Version:
7.0
Date of approval:
19 December 2025
Amendments:
Last amendment on 19 December 2025
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Authoring body:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare professionals involved in immunization programs
Period of validity:
17 December 2025 - 17 December 2028
Approval date:
9 December 2025
Review date:
17 July 2028
Expiry date:
17 December 2028
Year:
2025
Region / City:
United Kingdom
Topic:
Meningococcal Disease, Ciprofloxacin, Public Health
Document Type:
Clinical Guidance
Organization / Institution:
UK Health Security Agency (UKHSA)
Author:
Shilan Ghafoor, Dr. Shamez Ladhani, Kate Wedgwood
Target Audience:
Healthcare Practitioners, Public Health Authorities
Period of Validity:
From 20 October 2025
Approval Date:
10 October 2025
Expiry Date:
19 October 2028
Review Date:
19 October 2027
Year:
2025
Region / city:
Wales
Topic:
Inactivated influenza vaccine administration
Document type:
Addendum
Organization / institution:
NHS Wales
Author:
Welsh Medicines Advice Service (WMAS)
Target audience:
Registered healthcare professionals
Period of validity:
01 September 2025 - 31 March 2026
Approval date:
05 November 2025
Review date:
01 July 2026
Version:
1.0
Approval body:
Vaccine Clinical Advisory Group (VCAG)
Expiry date:
31 March 2026
Additional references:
Welsh Government. Health circulars. Available from https://www.gov.wales/health-circulars
Note:
[accessed 22 September 2025]
Context description:
Addendum to the NHS Wales Patient Group Direction (PGD) outlining the guidelines for administering inactivated influenza vaccines for the National Immunisation Programme 2025-2026.
Year:
2025
Region / City:
England
Topic:
Immunisation
Document Type:
Patient Group Direction (PGD)
Organisation / Institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Rebecca Cordery, Greta Hayward
Target Audience:
Healthcare practitioners
Period of Validity:
From 1 November 2025 to 1 November 2028
Approval Date:
24 September 2025
Revision Date:
23 September 2025
Year:
2025
Region / city:
United Kingdom
Topic:
Immunization, Influenza Vaccine
Document Type:
Addendum
Organization / Institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Alex Allen, Greta Hayward
Target Audience:
Health professionals, Immunization Programs
Effective Period:
1 September 2025 - 1 April 2026
Approval Date:
6 August 2025
Modification Date:
23 July 2025
Background:
Live attenuated influenza vaccine nasal spray suspension (Fluenz®) updated formula
Contextual Description:
Addendum to UKHSA PGD v15.0 detailing updates to the influenza vaccine composition and active strains.